Truist Financial Corp Has $394.16 Million Stake in Eli Lilly and Company $LLY

Key Points

• Truist Financial Corp increased its stake in Eli Lilly by 2.6% to 366,767 shares, worth $394,156,000 according to its latest SEC filing.
• Eli Lilly posted a strong Q1 beat—$8.55 EPS vs. $6.97 expected and $19.8B revenue (up 55.5% YoY)—set FY2026 guidance of 35.50–37.00 EPS, and holds a consensus rating of "Moderate Buy" with an average target near $1,217.59.
• The company is ramping capacity with an additional $4.5B Indiana investment and seeing early commercial traction for oral GLP‑1 pill Foundayo, but faces mounting competition from Novo Nordisk that could pressure pricing and share gains.

Truist Financial Corp grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 366,767 shares of the company's stock after buying an additional 9,384 shares during the period. Truist Financial Corp's holdings in Eli Lilly and Company were worth $394,156,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. raised its holdings in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth $356,000. Finally, Nebula Research & Development LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term efficacy data for Omvoh (mirikizumab) — LUCENT‑3 open‑label data show ~63.5% of patients who achieved disease clearance at one year maintained it at four years, reinforcing Omvoh’s durability in ulcerative colitis and strengthening Lilly’s IL‑23 franchise revenue outlook. Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
• Positive Sentiment: Foundayo oral GLP‑1 pill showing early commercial traction — reports say the oral obesity pill is adding prescribers and patients with broad pharmacy access and payer coverage, supporting a new revenue channel beyond injectables. Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• Positive Sentiment: Major manufacturing expansion — Lilly committed an additional $4.5B in Indiana (over $21B total since 2020) and opened a genetic‑medicine facility, which supports capacity for anticipated demand across biologics, small molecules and advanced therapies. This is a long‑term enabler of supply reliability. Lilly commits additional $4.5 billion across Indiana manufacturing sites
• Positive Sentiment: Earnings momentum and analyst support — recent Q1 beat‑and‑raise (strong Mounjaro and Zepbound sales) and analyst reiterations/targets underpin bullish sentiment and justify elevated valuation multiples. LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
• Neutral Sentiment: Dividend declared ($1.73/share, ex‑dividend May 15) — modest yield (≈0.7%) signals shareholder returns but is not a major near‑term price driver. Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
• Neutral Sentiment: Market chatter about financing — reports that Lilly is planning to sell roughly $8B of bonds to fund acquisitions could change capital structure and near‑term financing costs; company provided responses but investors will watch details. Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
• Negative Sentiment: Intense competition from Novo Nordisk — Novo’s strong pill launch and raised guidance highlight accelerating competitive pressure in the obesity/GLP‑1 market, which could cap pricing and market share gains for Lilly over time. Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance.
• Negative Sentiment: Market perception of product timing and pricing risk — coverage noting Novo’s momentum plus reports of delays/pressure in the oral GLP‑1 space raise short‑term uncertainty about Lilly’s obesity‑pill cadence and margin mix. Novo Nordisk Obesity Pill Momentum Meets Valuation Gap And Risk Flags

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Barclays boosted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a report on Tuesday, February 24th. They set an "outperform" rating and a $1,250.00 target price on the stock. BMO Capital Markets reissued an "outperform" rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a report on Thursday, February 5th. Finally, Leerink Partners dropped their price target on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating on the stock in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,217.59.

Eli Lilly and Company Trading Down 0.1%

Shares of NYSE:LLY opened at $987.52 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company's fifty day simple moving average is $945.26 and its 200 day simple moving average is $989.70. The firm has a market cap of $929.98 billion, a price-to-earnings ratio of 35.08, a PEG ratio of 1.08 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm's revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.58 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.